Total Funding
57
66
Total FundingGrant raised
Growth Score
-3 pts
Heat Score
-4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
42296
BioEclipse Therapeutics is a clinical-stage oncology company that develops immuno-oncology therapeutics using its proprietary technology.
- Gregory Schiffman: Chairman & Board MemberPast Role: Nanomix, Board Member and Chair of Audit Committee
- Robert Negrin: Co-Founder
About the Company
BioEclipse Therapeutics is a clinical-stage oncology company that develops immuno-oncology therapeutics using its proprietary technology. Its mission is to improve clinical outcomes and the quality of life for all cancer patients and to be at the forefront of turning cancer into a curable disease.
The company has harnessed a refined understanding
of the human immune system, gaining insights into the reasons the body’s defense system so often turns a blind eye to the presence of cancerous cells and tumors. In response, BioEclipse Therapeutics pairs activated immune cells with an adapted oncolytic virus that selectively infects and kills malignant cells.
Women Founded
Women Led
